Literature DB >> 31059280

Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.

Itziar Frades1, Ben Readhead1,2,3,4, Letizia Amadori1, Simon Koplev1, Husain A Talukdar5, Heidi M Crane6, Paul K Crane6, Jason C Kovacic7,8, Joel T Dudley1,2,3, Chiara Giannarelli1,8,9, Johan L M Björkegren1,2,5, Inga Peter1,2.   

Abstract

BACKGROUND: Antiretroviral therapy (ART) for HIV infection increases risk for coronary artery disease (CAD), presumably by causing dyslipidemia and increased atherosclerosis. We applied systems pharmacology to identify and validate specific regulatory gene networks through which ART drugs may promote CAD.
METHODS: Transcriptional responses of human cell lines to 15 ART drugs retrieved from the Library of Integrated Cellular Signatures (overall 1127 experiments) were used to establish consensus ART gene/transcriptional signatures. Next, enrichments of differentially expressed genes and gene-gene connectivity within these ART-consensus signatures were sought in 30 regulatory gene networks associated with CAD and CAD-related phenotypes in the Stockholm Atherosclerosis Gene Expression study.
RESULTS: Ten of 15 ART signatures were significantly enriched both for differential expression and connectivity in a specific atherosclerotic arterial wall regulatory gene network (AR-RGN) causal for CAD involving RNA processing genes. An atherosclerosis in vitro model of cholestryl ester-loaded foam cells was then used for experimental validation. Treatments of these foam cells with ritonavir, nelfinavir, and saquinavir at least doubled cholestryl ester accumulation ( P=0.02, 0.0009, and 0.02, respectively), whereas RNA silencing of the AR-RGN top key driver, PQBP1 (polyglutamine binding protein 1), significantly curbed cholestryl ester accumulation following treatment with any of these ART drugs by >37% ( P<0.05).
CONCLUSIONS: By applying a novel systems pharmacology data analysis framework, 3 commonly used ARTs (ritonavir, nelfinavir, and saquinavir) were found altering the activity of AR-RGN, a regulatory gene network promoting foam cell formation and risk of CAD. Targeting AR-RGN or its top key driver PQBP1 may help reduce CAD side effects of these ART drugs.

Entities:  

Keywords:  HIV; antiretroviral therapy, highly active; atherosclerosis; nelfinavir; ritonavir; saquinavir

Mesh:

Substances:

Year:  2019        PMID: 31059280      PMCID: PMC6601350          DOI: 10.1161/CIRCGEN.118.002390

Source DB:  PubMed          Journal:  Circ Genom Precis Med        ISSN: 2574-8300


  33 in total

1.  Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.

Authors:  Véronique Joly; Philippe Flandre; Vincent Meiffredy; Nicolas Leturque; Marine Harel; Jean-Pierre Aboulker; Patrick Yeni
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

Review 2.  Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.

Authors:  David C Rhew; Myriam Bernal; Daniel Aguilar; Uchenna Iloeje; Matthew Bidwell Goetz
Journal:  Clin Infect Dis       Date:  2003-09-12       Impact factor: 9.079

Review 3.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 4.  HIV protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

5.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

6.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

7.  Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Authors:  Nina Friis-Møller; Rainer Weber; Peter Reiss; Rodolphe Thiébaut; Ole Kirk; Antonella d'Arminio Monforte; Christian Pradier; Linda Morfeldt; Silvia Mateu; Matthew Law; Wafaa El-Sadr; Stephan De Wit; Caroline A Sabin; Andrew N Phillips; Jens D Lundgren
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

8.  Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

Authors:  Murielle Mary-Krause; Laurent Cotte; Anne Simon; Maria Partisani; Dominique Costagliola
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

9.  Combination antiretroviral therapy and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

10.  Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

Authors:  Daniel Klein; Leo B Hurley; Charles P Quesenberry; Stephen Sidney
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-15       Impact factor: 3.731

View more
  3 in total

Review 1.  Connections for Matters of the Heart: Network Medicine in Cardiovascular Diseases.

Authors:  Abhijeet Rajendra Sonawane; Elena Aikawa; Masanori Aikawa
Journal:  Front Cardiovasc Med       Date:  2022-05-19

Review 2.  Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations.

Authors:  Alexander M Markin; Igor A Sobenin; Andrey V Grechko; Dongwei Zhang; Alexander N Orekhov
Journal:  Front Pharmacol       Date:  2020-05-14       Impact factor: 5.810

Review 3.  The Interface of Therapeutics and Genomics in Cardiovascular Medicine.

Authors:  E F Magavern; J C Kaski; R M Turner; A Janmohamed; P Borry; M Pirmohamed
Journal:  Cardiovasc Drugs Ther       Date:  2021-02-02       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.